GRAIL (GRAL) Set to Release Quarterly Earnings on Wednesday

GRAIL (NASDAQ:GRAL) is expected to be issuing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect GRAIL to announce earnings of ($2.45) per share and revenue of $44.21 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

GRAIL (NASDAQ:GRAL) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) EPS for the quarter, topping analysts’ consensus estimates of ($2.66) by $0.10. The firm had revenue of $44.69 million for the quarter, compared to analysts’ expectations of $42.39 million. On average, analysts expect GRAIL to post ($10.07) EPS for the current fiscal year and ($10.80) EPS for the next fiscal year.

GRAIL Trading Up 5.1%

Shares of NASDAQ GRAL traded up $7.64 during midday trading on Wednesday, hitting $158.25. The company’s stock had a trading volume of 230,451 shares, compared to its average volume of 969,547. The business’s 50 day moving average is $107.27 and its two-hundred day moving average is $77.77. GRAIL has a 12-month low of $41.50 and a 12-month high of $166.48. The firm has a market cap of $7.07 billion, a P/E ratio of -16.21 and a beta of 2.83.

Insider Activity

In related news, insider Andrew Partridge sold 7,873 shares of the firm’s stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $146.39, for a total transaction of $1,152,528.47. Following the sale, the insider owned 155,865 shares of the company’s stock, valued at $22,817,077.35. This trade represents a 4.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Joshua J. Ofman sold 61,452 shares of GRAIL stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $97.74, for a total value of $6,006,318.48. Following the completion of the transaction, the chief executive officer owned 362,271 shares in the company, valued at $35,408,367.54. This trade represents a 14.50% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 129,944 shares of company stock worth $14,832,805. 1.83% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

GRAL has been the subject of a number of recent analyst reports. Wall Street Zen upgraded GRAIL from a “sell” rating to a “hold” rating in a report on Sunday, September 13th. Mizuho upped their price objective on GRAIL from $65.00 to $100.00 and gave the company a “neutral” rating in a research report on Friday, September 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of GRAIL in a research note on Thursday, October 15th. Guggenheim lifted their target price on GRAIL from $75.00 to $155.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Finally, Robert W. Baird boosted their target price on shares of GRAIL from $96.00 to $118.00 and gave the company an “outperform” rating in a research note on Tuesday, September 22nd. Five investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $119.80.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a healthcare company focused on developing blood-based screening technologies for the early detection of cancer. Its principal product is Galleri, a multi-cancer early detection test designed to identify DNA patterns associated with multiple types of cancer from a single blood sample.

Galleri is intended for use alongside recommended cancer screenings and is available by prescription through qualified healthcare providers in the United States. The test is offered as a laboratory-developed test and has not been approved or cleared by the U.S.